The ADIUVO trial, the first RCT comparing adjuvant mitotane therapy to surveillance in resected ACC patients with low to intermediate risk (stage I-III, R0 resection, Ki67 ≤ 10%), reported no significant benefit of adjuvant mitotane in improving RFS or OS (40). Here, MKI67 is linked to adrenal cortex carcinoma.